Days Set Up
Monday - Thursday
Analytic Time

5-12 days

MiChart Code
KIT Mutation for Melanoma
Soft Order Code
MEL

Test Updated:

Synonyms

MLABEL
KIT Mutation Detection - Melanoma
MEL
KIT Mutation Detection for Imatinib Therapy
c-KIT Mutation
KIT Exon 11, 13, 17 Mutations
AKT1
ALK
AR
AXL
BRAF
CCND1
CDK4
CDK6
CTNNB1
DDR2
EGFR
EGFRvIII
ERBB2
(HER2)
ERBB3
ERBB4
ERG
ESR1
ETV1
ETV4
ETV5
FGFR1
FGFR2
FGFR3
FGFR4
GNA11
GNAQ
HRAS
IDH1
IDH2
JAK1
JAK2
JAK3
KIT
KRAS
MAP2K1
MAP2K2
MET
MTOR
MYC
MYCN
NRAS
NTRK1
NTRK2
NTRK3
PDGFRA
PIK3CA
PPARG
RAF1
RET
ROS1
SMO

Looking to order a test?

We’ve provided helpful links to make ordering easy.

Find a Requisition

All specimens should be accompanied by a requisition.

Submitting Specimens

Learn about how to properly label and where to ship specimens.

Order Kits and Supplies

MLabs provides all the supplies necessary for the collection of specimens.

Test FAQ

Visit our provider FAQ and learn about common questions to ordering tests.

Test Overview

Test Methodology

Next Generation Sequencing

Test Usage

Oncogenic mutations within the KIT gene occur in a subset of melanomas, most frequently in those of mucosal (~20%) and acral (~15%) types, and less commonly in those from cutaneous and conjunctival sites. These KIT mutations are predicted to be activating, and are similar to those found in imatinib-responsive cancers of other types. Testing for KIT mutation in melanoma may aid in identifying patients who might benefit from therapies such as imatinib that target activated KIT. This DNA test is performed by targeted next-generation sequencing (NGS) and will detect KIT mutations within the sequenced regions of exons 8, 9, 11, 13 and 17 (see Additional Information below for specific regions sequenced). Specimens should contain an adequate proportion of neoplastic nuclei (>10%) in the areas to be extracted to ensure mutation detection.

Reference Range

Interpretive report provided.

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Specimen Requirements

Collection Onsite

For formalin-fixed, paraffin-embedded tissue, a block containing an area with a high percentage of neoplastic cells (for micro-/macro-dissection) is preferred. Unstained, UNBAKED slides (5-8, 10-micron slides; 10-15 if few neoplastic cells are present) with associated H&E stained slide are also acceptable. Decalcified tissue or other fixatives will be accepted and the assay attempted, however these may result in failed testing due to degraded nucleic acid. Both blocks and slides should be stored at room temperature. A Diff-Quik or Papanicolaou stained aspirate smear (preferable containing a high percentage and overall amount of neoplastic cells) is also acceptable. Store at room temperature.

Collection Offsite

For formalin-fixed, paraffin-embedded tissue, a block containing an area with a high percentage of neoplastic cells (for micro-/macro-dissection) is preferred. Unstained, UNBAKED slides (5-8, 10-micron slides; 10-15 if few neoplastic cells are present) with associated H&E stained slide are also acceptable. Decalcified tissue or other fixatives will be accepted and the assay attempted, however these may result in failed testing due to degraded nucleic acid. Both blocks and slides should be stored at room temperature. A Diff-Quik or Papanicolaou stained aspirate smear (preferable containing a high percentage and overall amount of neoplastic cells) is also acceptable. Store at room temperature.

Normal Volume
Formalin-fixed, paraffin-embedded tissue; Diff-Quik stained aspirate smear, Papanicolaou stained aspirate smear. Extracted DNA is also acceptable if extracted in a CLIA certified laboratory.
Minimum Volume
 

Billing Information

CPT Code
81272, 88381-TC
Pro Fee Code
 
LOINC
 

Have More Questions?

Explore our helpful billing resources:

Our High Standard

Quality that sets us apart

As the reference laboratory division of Michigan Medicine's Department of Pathology, MLabs shares the institution's commitment to applying established quality principles to clinical laboratory testing. Like other large organizations in complex, consequential fields, we rely on an established approach to monitor quality throughout the testing process.